Zim Laboratories Peer Comparison

NSE: ZIMLAB | BSE: 541400

₹144.76

₹4.46 (3.18%)

As on 16-Oct-2026IST

Market cap

₹780 Cr

Revenue (TTM)

₹397 Cr

P/E Ratio

210.9

P/B Ratio

2.7

Div. Yield

0 %

Edit

	Zim Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	780	18,336	17,484	17,475	15,832
Revenue (₹ Cr)	397	1,682	2,287	2,570	3,230
Net Profit (₹ Cr)	3.70	273.51	678.07	735.15	666.92
Net Margin (%)	0.91	16.19	28.10	26.88	20.60
RoE (%)	1.35	11.15	19.73	19.16	18.75
Price to Earnings	210.95	61.67	26.28	23.77	24.59
Price-To-Book	2.68	6.83	4.76	3.97	3.93

Income Statement (₹ Cr)

	Zim Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Operating Revenue	396.82	1,682.47	2,287.33	2,569.77	3,229.67
Total Income	407.72	1,689.83	2,413.29	2,735.39	3,237.12
Total Expenditure	368.62	1,203.91	1,490.75	1,628.14	2,090.06
EBITDA	28.20	478.55	796.58	941.63	1,139.61
Depreciation	20.49	126.01	78.10	57.58	281.06
EBIT	7.72	352.55	718.48	884.05	858.55
Interest	13.54	52.11	0.88	7.69	190.64
Other Income	10.90	7.37	125.96	165.62	7.45
Exceptional Items	0.00	12.16	0.00	-49.16	-17.24
Profit before Tax	5.07	319.96	843.56	992.82	658.12
Provision for Tax	1.38	46.45	165.49	257.67	-8.80
Profit after Tax	3.70	273.51	678.07	735.15	666.92

	Zim Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Shareholder's Funds	296.15	2,591.20	3,586.42	4,202.90	3,902.67
Minority Interest	0.00	0.00	-12.71	0.00	-21.81
Non-Current Liabilities	52.84	266.35	28.74	91.50	1,392.75
Current Liabilities	190.39	848.06	385.94	627.48	2,077.10
Total Liabilities	539.75	3,705.61	4,037.51	4,921.88	7,246.72

	Zim Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Non-Current Assets	257.82	2,525.44	1,291.22	770.28	5,617.77
Current Assets	275.81	1,109.77	2,585.66	3,803.22	1,539.85
Total Assets	539.75	3,705.61	4,037.51	4,921.88	7,246.72
Total Debt*	122.82	657.97	0.57	2.50	2,309.68
Net Current Assets	85.42	261.71	2,199.72	3,175.74	-537.25
Contingent Liabilities	10.10	160.01	17.53	370.49	51.57

	Zim Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Cash From Operating Activities	49.53	342.18	523.24	967.57	537.99
Cash Flow from Investing Activities	-56.35	-325.92	-582.30	-561.67	-369.46
Cash from Financing Activities	28.19	13.62	-46.46	-798.31	-313.53
Net Cash Inflow / Outflow	21.37	29.88	-105.52	-392.41	-145.00

	Zim Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
ROCE (%)	5.47	11.43	24.97	23.39	14.47
ROE (%)	1.35	11.15	19.73	19.16	18.75
ROA (%)	0.73	7.80	18.69	14.95	9.26
EBIT Margin (%)	1.94	20.95	31.41	34.40	26.58
Net Margin (%)	0.91	16.19	28.10	26.88	20.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Zim Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Revenue Growth (%)	7.55	27.91	15.01	10.69	9.59
EBIT Growth (%)	-61.26	58.32	18.45	24.14	16.84
Net Profit Growth (%)	-60.63	149.56	19.61	-9.09	62.68
EPS Growth (%)	-60.34	-3.57	17.73	14.40	67.41
Book Value Growth (%)	17.07	9.67	26.75	-0.34	36.71

	Zim Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Price / Earnings	190.10	65.42	26.28	22.65	23.97
Price / Book Value	2.68	6.83	4.76	3.97	3.93
Dividend Yield (%)	0.00	0.06	0.35	1.96	0.00
EV/EBITDA	30.46	39.60	20.69	15.26	15.86
Market Cap (₹ Cr)	320.30	6,819.66	11,439.22	21,592.90	17,980.08

	Zim Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debt to Equity	0.14	0.07	0.00	0.00	0.24
Short term debt to equity ratio	0.21	0.16	0.00	0.00	0.12
Current Ratio	1.45	1.31	6.70	6.06	0.74
Quick Ratio	0.96	0.88	5.59	5.31	0.53
Interest Coverage	1.37	7.14	959.59	130.11	4.45

	Zim Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debtors to sales (%)	27.48	30.84	36.10	7.07	21.07
Asset Turnover	0.78	0.48	0.63	0.52	0.45
Receivable days	105.27	113.81	121.68	26.06	63.88
Inventory Days	87.86	84.76	63.83	65.95	43.27
Payable days	157.18	101.94	108.28	81.01	151.85
Cash Conversion Cycle	35.94	96.62	77.23	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.